Bausch + Lomb Announces Final Results for Its Previously Announced Tender Offer for Its 9 7/8% Senior Notes due 2015 (CUSIP Nos. 071707AN3, U07190AA6 and 071707AP8)

ROCHESTER, N.Y., Aug. 20, 2012 /PRNewswire/ -- Bausch & Lomb Incorporated ("Bausch + Lomb") announced today the final results of its previously announced tender offer (the "tender offer") to purchase for cash up to $300 million of its outstanding 9 ⅞ percent Senior Notes due 2015 (CUSIP Nos. 071707AN3, U07190AA6 and 071707AP8) (the "senior notes").

As of the previously announced "expiration date" of 11:59 p.m., New York City time, on August 17, 2012, according to Global Bondholder Services Corporation, which acted as the tender and information agent for the tender offer, $74,691,000 aggregate principal amount of senior notes were validly tendered and not withdrawn.  Bausch + Lomb has accepted for purchase all senior notes that were validly tendered and not withdrawn prior to the expiration date.

Bausch + Lomb is also announcing an extension of the previously announced settlement date for the tender offer, which is now expected to be August 22, 2012.

The complete terms and conditions of the tender offer are described in the Bausch + Lomb Offer to Purchase dated July 23, 2012.  Citigroup served as the dealer manager for the tender offer.

This press release does not constitute an Offer to Purchase or a solicitation of an Offer to Sell our senior notes or other securities, nor shall there be any purchase of senior notes in any state or jurisdiction in which such offer, solicitation or purchase would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. The tender offer was made solely by and pursuant to the Bausch + Lomb Offer to Purchase dated July 23, 2012.

About Bausch + Lomb

Bausch + Lomb is one of the best-known and most respected healthcare companies in the world. Its core businesses include contact lenses and lens care products, ophthalmic surgical devices and instruments, and ophthalmic pharmaceuticals. Founded in 1853, the company is headquartered in Rochester, NY, and employs more than 11,000 people worldwide. Its products are available in more than 100 countries. More information is available at

Forward-Looking Statements

Some of the statements in this press release and in Bausch + Lomb's Offer to Purchase contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, or the "Securities Act," and Section 21E of the Securities Exchange Act of 1934, as amended, or the "Exchange Act." Forward-looking statements are often characterized by the use of words such as "believe," "estimate," "expect," "project," "may," "intend," "plan" or "anticipate." Such forward-looking statements involve known and unknown risks, uncertainties, assumptions and other important factors that could cause Bausch + Lomb's actual results, performance or achievements to be materially different from historical results, any future results, or performance or achievements expressed or implied by such forward-looking statements. When considering these forward-looking statements, holders of senior notes should keep in mind the cautionary statements in the Offer to Purchase.  In addition, new risks and uncertainties may arise from time to time. Accordingly, all forward-looking statements should be evaluated with an understanding of their inherent uncertainty. All subsequent written and oral forward-looking statements attributable to Bausch + Lomb or persons acting on Bausch + Lomb's behalf are expressly qualified in their entirety by these cautionary statements. The forward-looking statements included herein are made only as of the date of this press release, and Bausch + Lomb does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

News Media Contact:

Elizabeth Murphy
Global Communications
(585) 338-8528 or [email protected]

Investor Relations Contact:

Daniel Ritz
Investor Relations
(585) 338-5802 or [email protected]

SOURCE Bausch + Lomb Incorporated